Prescription Drug Supply Chain Pricing Transparency Act

This bill would require the Government Accountability Office (GAO), led by the Comptroller General, to study how payments and fees tied to a prescription drug's price are used in the retail drug supply chain. The study would cover pharmacy benefit managers, Medicare Part D plan sponsors, drug wholesalers, pharmacies, manufacturers, and other middlemen and advisers. It would look at business models, differences between affiliated and unaffiliated companies, possible conflicts of interest, and trends over time, including in Medicare Part D and Medicaid. The GAO would have to send Congress a report with its findings and any recommendations within 2 years of the law taking effect.

Full text and official record on Congress.gov

Sponsors

• Michael F. Bennet Democrat sponsor
• 1 cosponsors